Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8227154 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 6 Pages |
Abstract
Among patients with a history of CHF or MI treated with brachytherapy-based radiation, ADT was associated with increased all-cause mortality, even for patients with high-risk disease. Although ADT has been shown in Phase III studies to improve overall survival in high-risk disease, the small subgroup of high-risk patients with a history of CHF or MI, who represented about 9% of the patients, may be harmed by ADT.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Paul L. M.D., Ming-Hui Ph.D., Joshua A. M.D., M.S., Clair J. M.D., Neil E. M.D., M.P.H., Toni K. M.D., Jim C. M.D., M.P.H., Karen E. M.D., M.P.H., M.H.Sc., Daniel E. M.D., Brian J. M.D., Sharon A. M.P.H., Michelle H. Braccioforte, Philip W. M.D.,